Skip to main content
. 2017 Jan 6;17:28. doi: 10.1186/s12885-016-3021-7

Table 1.

Clinicopathologic Characteristics of three groups according to Ki67-LI level

Characteristic Ki67 ≤ 10%
n = 342
10% < Ki67 < 30%
n = 281
Ki67 ≥ 30%
n = 316
Total
N = 939
P value
Associated events-no.(%) 10(2.9) 20(7.1) 49(15.5) 79(8.4)
Age
 Median(IQT)-yr 49(23–86) 48(24–91) 47(22–84) 48(22–91) 0.166
 Distribution-no.(%) 0.013
 < 35 19(5.6) 15(5.3) 31(9.8) 65(6.9)
 35–50 160(46.8) 148(52.7) 163(51.6) 471(50.2)
 51–65 122(35.7) 93(33.1) 102(32.3) 317(33.8)
 > 65 41(12.0) 25(8.9) 20(6.3) 86(9.2)
Menopausal status-no.(%) 0.011
 Pre 171(50.0) 122(43.4) 176(55.7) 469(49.9)
 Post/Peri 171(50.0) 159(56.6) 140(44.3) 470(50.0)
Histology-no.(%) <0.001
 IDC 273(79.8) 236(84.0) 297(94.0) 806(85.8)
 ILC 10(2.9) 10(3.6) 6(1.9) 26(2.8)
 Mucinous 25(7.3) 13(4.6) 4(1.3) 42(4.5)
 Other invasive histology 34(9.9) 22(7.8) 9(2.8) 65(6.9)
pT-no./total no.(%) <0.001
 1 239/336(71.1) 181/276(65.6) 159/307(51.8) 579/919(63.0)
 2 91/336(27.1) 86/276(31.2) 139/307(45.3) 316/919(34.4)
 3 6/336(1.8) 9/276(3.3) 9/307(2.9) 24/919(2.6)
Node-no.(%) 0.022
 N0 249(72.8) 180(64.1) 202(63.9) 631(67.2)
 N1 93(27.2) 101(35.9) 114(36.1) 308(32.8)
LVI-no.(%) 0.074
 Positive 49(14.3) 59(21.0) 61(19.3) 169(18.0)
 Negative 293(85.7) 222(79.0) 255(80.7) 770(82.0)
Grade-no./total no.(%) <0.001
 I/II 269/289(93.1) 189/241(78.4) 137/282(48.6) 595/812(73.3)
 III 20/289(6.9) 52/241(21.6) 145/282(51.4) 217/812(26.7)
PgR-no.(%) <0.001
 < 20% 58(17.0) 55(19.6) 119(37.7) 232(24.7)
 ≥ 20% 284(83.0) 226(80.4) 197(62.3) 707(75.3)
Surgery-no.(%) 0.479
 BCS 202(59.1) 178(63.3) 187(59.2) 567(60.4)
 Mastectomy 140(40.9) 103(36.7) 129(40.8) 372(39.6)
Chemotherapy-no.(%) <0.001
 Yes 252(73.7) 234(83.3) 290(91.8) 776(82.6)
 No 90(26.3) 47(16.7) 26(8.2) 163(17.4)
Radiotherapy-no.(%) 0.033
 Yes 237(69.3) 217(77.2) 243(76.9) 697(74.2)
 No 105(30.7) 64(22.8) 73(23.1) 242(25.8)

IQT interquartile range, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, LVI lymphovascular invasion, PgR progesterone receptor, BCS breast-conserving surgery